Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the firm's stock in a transaction on Wednesday, January 8th. The stock was bought at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the purchase, the insider now owns 7,800,000 shares in the company, valued at approximately $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA traded down $0.20 during mid-day trading on Monday, hitting $4.84. 981,563 shares of the company's stock traded hands, compared to its average volume of 1,431,138. Olema Pharmaceuticals, Inc. has a 1 year low of $4.60 and a 1 year high of $16.77. The company's 50-day moving average is $8.35 and its two-hundred day moving average is $11.01. The company has a market capitalization of $277.32 million, a P/E ratio of -2.21 and a beta of 2.05.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OLMA. Conway Capital Management Inc. purchased a new position in shares of Olema Pharmaceuticals in the 3rd quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. lifted its position in Olema Pharmaceuticals by 67.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company's stock worth $132,000 after buying an additional 4,442 shares during the last quarter. Portland Investment Counsel Inc. purchased a new position in Olema Pharmaceuticals during the third quarter worth $143,000. Cubist Systematic Strategies LLC bought a new position in Olema Pharmaceuticals during the second quarter valued at $145,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Olema Pharmaceuticals in the third quarter valued at $156,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Olema Pharmaceuticals has a consensus rating of "Buy" and an average target price of $27.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.